Risultati della ricerca - Richard D. DiMarchi

Raffina i risultati
  1. 1
    Fibroblast growth factor 21 night watch: advances and uncertainties in the field

    Fibroblast growth factor 21 night watch: advances and uncertainties in the field di Alexei Kharitonenkov, Richard D. DiMarchi

    Pubblicazione 2016
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety

    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety di Rongjun He, Brian Finan, John P. Mayer, Richard D. DiMarchi

    Pubblicazione 2019
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Anti-obesity drug discovery: advances and challenges

    Anti-obesity drug discovery: advances and challenges di Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, Richard D. DiMarchi

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists di Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, M. Tschöp

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Optimization of the Native Glucagon Sequence for Medicinal Purposes

    Optimization of the Native Glucagon Sequence for Medicinal Purposes di Joseph R. Chabenne, Maria A. DiMarchi, Vasily M. Gelfanov, Richard D. DiMarchi

    Pubblicazione 2010
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology di Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    Insulin analogues and their potential in the management of diabetes mellitus

    Insulin analogues and their potential in the management of diabetes mellitus di Geremia B. Bolli, Richard D. Di Marchi, G. D. Park, Stig Pramming, Veikko A Koivisto

    Pubblicazione 1999
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis

    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis di Joseph P. Tiano, Chandra R. Tate, Bin Yang, Richard D. DiMarchi, Franck Mauvais‐Jarvis

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes di Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, Jonathan E. Campbell

    Pubblicazione 2018
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    The metabolic actions of glucagon revisited

    The metabolic actions of glucagon revisited di Kirk M. Habegger, Kristy M. Heppner, Nori Geary, Timothy J. Bartness, Richard D. DiMarchi, Matthias H. Tschöp

    Pubblicazione 2010
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment

    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment di Shravan Babu Girada, Ramya S. Kuna, Shilpak Bele, Zhimeng Zhu, N.R. Chakravarthi, Richard D. DiMarchi, Prasenjit Mitra

    Pubblicazione 2017
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice

    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice di Kristy M. Heppner, Sarah Marks, Jenna Holland, Nickki Ottaway, David L. Smiley, Richard D. DiMarchi, Diego Pérez–Tilve

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Peptide lipidation stabilizes structure to enhance biological function

    Peptide lipidation stabilizes structure to enhance biological function di Brian Ward, Nickki Ottaway, Diego Pérez–Tilve, Dejian Ma, Vasily M. Gelfanov, Matthias H. Tschöp, Richard D. DiMarchi

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    GLP-1/glucagon receptor co-agonism for treatment of obesity

    GLP-1/glucagon receptor co-agonism for treatment of obesity di Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

    Pubblicazione 2017
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  15. 15
    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism di Piotr Mróz, Brian Finan, Vasily M. Gelfanov, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi, Diego Pérez–Tilve

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications di Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio

    Pubblicazione 2023
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  17. 17
    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity di Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi

    Pubblicazione 2016
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  18. 18
    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes di Qiming Tan, Seun Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller, Andrea M. Haqq

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  19. 19
    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia

    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia di Joseph R. Chabenne, Maria DiMarchi Chabenne, Yan Zhao, Jay J. Levy, David L. Smiley, Vasily M. Gelfanov, Richard D. DiMarchi

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice di Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller, Susanna M. Hofmann

    Pubblicazione 2017
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: